Tysabri Return To Market With Expanded Indication Backed By Committee
Executive Summary
Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8
You may also be interested in...
FDA Approving More Novel Drugs Without Advisory Committee Review
The Center for Drug Evaluation and Research is becoming more comfortable approving new molecular entities and novel biologics without first seeking the views of its outside experts. In 2011, 13 of the 30 novel therapeutics cleared did not undergo advisory committee scrutiny beforehand.
Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy
Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy